- Apollomics Inc. (APLM) announced on **August 28, 2025**, the **termination of all U.S. employees**, including the CEO and CFO, effective **August 29, 2025**, and the expected **discontinuation of all SPARTA clinical trial activities** due to its cash position.  **[1944885_0001193125-25-190310_d51002d6k.htm:0]** 
- The company will hold an **Extraordinary General Meeting of Shareholders** on **September 4, 2025**, to seek approval for the **voluntary winding up of the Company**.  **[1944885_0001193125-25-190310_d51002d6k.htm:0]** **[1944885_0001193125-25-190310_d51002dex991.htm:0]** 
- The Board is recommending the winding up because the company is **unable to continue operations or pay its debts** and has been **unable to secure additional financing**.  **[1944885_0001193125-25-190310_d51002dex991.htm:2]** **[1944885_0001193125-25-190310_d51002dex991.htm:6]** 
- It is **unclear whether there will be any distributions for shareholders** if the winding up is approved, and the company **does not expect any distributions** for shareholders, warrant holders, or option holders.  **[1944885_0001193125-25-190310_d51002dex991.htm:3]** **[1944885_0001193125-25-190310_d51002dex991.htm:7]**

Apollomics (APLM)